Recommendations for Clinical CYP2C19 Genotyping Allele Selection

Enroll

This content was created in 2018, but has been reviewed and approved by the Training & Education Committee as useful, accurate, and relevant. Please note that in the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.

AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.

Description: 

In this webinar, Dr. Karen Weck will present the recommendations of The AMP Pharmacogenomics Working Group of the Clinical Practice Committee for inclusion of variants in CYP2C19 genotyping panels. The working group has published consensus, evidence-based recommendations using criteria such as allele function, population frequency, and availability of reference materials. The recommendations include a Tier 1 minimum set of alleles and defining variants that should be included in all clinical CYP2C19 PGx tests, and a Tier 2 list of additional optional alleles that do not currently meet all of the criteria for inclusion in Tier 1. These recommendations are intended to aid clinical laboratory professionals when designing and validating CYP2C19 genotyping assays, promote standardization of testing across different laboratories, and complement existing clinical guidelines for pharmacogenetic testing.

Learning Objectives:

  • List the three most common alleles associated with CYP2C19 altered metabolism and their respective effects on enzymatic function.
  • Give examples of key drugs in clinical use that are affected by CYP2C19 genetic variability affecting enzymatic activity.
  • Describe the key characteristics of pharmacogenetic alleles that are recommended for inclusion in clinical testing platforms by the AMP PGx working group.

Practice Guideline Available Here

Speaker: Karen E. Weck, MD
Moderator: Joshua Deignan, PhD
Duration: 1 hr
Level of Instruction: Basic
Date Recorded: March 21, 2018

Continuing Education Credit Information

CE Credit for this course has expired.

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Enroll